698 related articles for article (PubMed ID: 19672839)
21. Sensitivity of dose-finding studies to observation errors.
Zohar S; O'Quigley J
Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
[TBL] [Abstract][Full Text] [Related]
22. Design issues in dose-finding Phase I trials for combinations of two agents.
Fan SK; Venook AP; Lu Y
J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
[TBL] [Abstract][Full Text] [Related]
23. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
24. Continual reassessment method: a likelihood approach.
O'Quigley J; Shen LZ
Biometrics; 1996 Jun; 52(2):673-84. PubMed ID: 8672707
[TBL] [Abstract][Full Text] [Related]
25. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
Horton BJ; Wages NA; Conaway MR
Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method.
Legedza AT; Ibrahim JG
Stat Med; 2001 Mar; 20(6):867-82. PubMed ID: 11252009
[TBL] [Abstract][Full Text] [Related]
27. An adaptive dose-finding design incorporating both toxicity and efficacy.
Zhang W; Sargent DJ; Mandrekar S
Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
[TBL] [Abstract][Full Text] [Related]
28. Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.
Doussau A; Asselain B; Le Deley MC; Geoerger B; Doz F; Vassal G; Paoletti X
Contemp Clin Trials; 2012 Jul; 33(4):657-65. PubMed ID: 22521954
[TBL] [Abstract][Full Text] [Related]
29. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
Pan H; Yuan Y
Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
[TBL] [Abstract][Full Text] [Related]
30. Two-sample continual reassessment method.
O'Quigley J; Shen LZ; Gamst A
J Biopharm Stat; 1999 Mar; 9(1):17-44. PubMed ID: 10091908
[TBL] [Abstract][Full Text] [Related]
31. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
Yin G; Li Y; Ji Y
Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
[TBL] [Abstract][Full Text] [Related]
32. np1: a computer program for dose escalation strategies in phase I clinical trials.
Kramar A; Houédé N; Paoletti X
Comput Methods Programs Biomed; 2007 Oct; 88(1):8-17. PubMed ID: 17719124
[TBL] [Abstract][Full Text] [Related]
33. Sequential designs for logistic phase I clinical trials.
Liu G; Rosenberger WF; Haines LM
J Biopharm Stat; 2006; 16(5):605-21. PubMed ID: 17037261
[TBL] [Abstract][Full Text] [Related]
34. Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.
Doussau A; Thiébaut R; Paoletti X
Stat Med; 2013 Dec; 32(30):5430-47. PubMed ID: 24018535
[TBL] [Abstract][Full Text] [Related]
35. Small-sample confidence sets for the MTD in a phase I clinical trial.
Storer BE
Biometrics; 1993 Dec; 49(4):1117-25. PubMed ID: 8117905
[TBL] [Abstract][Full Text] [Related]
36. Retrospective analysis of sequential dose-finding designs.
O'Quigley J
Biometrics; 2005 Sep; 61(3):749-56. PubMed ID: 16135026
[TBL] [Abstract][Full Text] [Related]
37. Bayesian model averaging continual reassessment method for bivariate binary efficacy and toxicity outcomes in phase I oncology trials.
Asakawa T; Hirakawa A; Hamada C
J Biopharm Stat; 2014; 24(2):310-25. PubMed ID: 24605971
[TBL] [Abstract][Full Text] [Related]
38. Dose-finding in phase I clinical trials based on toxicity probability intervals.
Ji Y; Li Y; Nebiyou Bekele B
Clin Trials; 2007; 4(3):235-44. PubMed ID: 17715248
[TBL] [Abstract][Full Text] [Related]
39. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
Hirakawa A
Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
[TBL] [Abstract][Full Text] [Related]
40. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
Messer K; Natarajan L; Ball ED; Lane TA
Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]